Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (131-140 of 264) with videos related to

Pageof 27
Sort By:
Journal of the National Cancer Institute|June 26, 2008
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinaseJi Wu, Feng Meng, Ling-Yuan Kong, et al.
Cancer|April 25, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|April 27, 2018
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphomaTycel J Phillips, Andres Forero-Torres, Taimur Sher, et al.
Blood|March 15, 2003
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes, Francis Giles, Susan O'Brien, et al.
Blood|August 30, 2003
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingRazelle Kurzrock, Hagop M Kantarjian, Jorge E Cortes, et al.
Radiology. Imaging Cancer|November 14, 2025
Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective StudyTanner H Robison, Annabel Levinson, Winston Lee, et al.
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2003
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-LYan Yan, Leuyen Phan, Fan Yang, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Identification of Omaveloxolone as An Endoplasmic Reticulum Associated Degradation Inhibitor That Induces Early Apoptotic Signaling in Multiple MyelomaErin M Kropp, Sho Matono, Olivia Y Wang, et al.
Pageof 27

Showing results (131-140 of 264) with videos related to

Sort By:
Pageof 27
Journal of the National Cancer Institute|June 26, 2008
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinaseJi Wu, Feng Meng, Ling-Yuan Kong, et al.
Cancer|April 25, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|April 27, 2018
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphomaTycel J Phillips, Andres Forero-Torres, Taimur Sher, et al.
Blood|March 15, 2003
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes, Francis Giles, Susan O'Brien, et al.
Blood|August 30, 2003
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingRazelle Kurzrock, Hagop M Kantarjian, Jorge E Cortes, et al.
Radiology. Imaging Cancer|November 14, 2025
Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective StudyTanner H Robison, Annabel Levinson, Winston Lee, et al.
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 23, 2003
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-LYan Yan, Leuyen Phan, Fan Yang, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Identification of Omaveloxolone as An Endoplasmic Reticulum Associated Degradation Inhibitor That Induces Early Apoptotic Signaling in Multiple MyelomaErin M Kropp, Sho Matono, Olivia Y Wang, et al.
Pageof 27